CRISPR’s Nobel Prize sent gene-editing stocks into overdrive
It’s been a great month for CRISPR stocks
Wall Street rates CRISPR-powered stocks
CRISPR offers a relatively cheap and relatively method of editing practically any kind of DNA (animal or otherwise).
As one might expect, it’s already triggered a myriad of moral, ethical, and legal troubles for scientists, but researchers say the tool could lead to cures for a wide array of genetic diseases.
[Read: Esports and gaming stocks are returning more profit than Bitcoin]
For what it’s worth, Bank of America (BoA) finds the hype justified, at least in the short-term. BoA analystsreportedly issuedtheir first rating to CRSP earlier this week: “Buy” with a price target of $110 (current price $96).
Goldman Sachs also rated NTLA for the first time last month when it labelled it a “Buy” and set its price target to $33 (current price $23), according tofinance portal Finviz.
None of this is investment advice. Don’t pretend it is, because it’s not. Always do your own research.
Story byDavid Canellis
David is a tech journalist who loves old-school adventure games, techno and the Beastie Boys. He’s currently on the finance beat.David is a tech journalist who loves old-school adventure games, techno and the Beastie Boys. He’s currently on the finance beat.
Get the TNW newsletter
Get the most important tech news in your inbox each week.
